Dogwood TherapeuticsNASDAQ: DWTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Website:

http://www.dwtx.com

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A

Market cap

$3.96 M
-94%vs. 3y high
12%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

4.17
-58%vs. 3y high
79%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$2.97-$0.23(-7.19%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$2.05-$1.42

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--$2.28 M

Analysts recommendations

Total assets

Total liabilities

$2.28 M$1.33 M

Institutional Ownership

Included in screeners

No data

Similar companies

Hepion Pharmaceuticals logo

Hepion Pharmaceuticals (HEPA)

Aptevo Therapeutics logo

Aptevo Therapeutics (APVO)

Aptorum Group Limited logo

Aptorum Group Limited (APM)

Purple Biotech logo

Purple Biotech (PPBT)

Genprex logo

Genprex (GNPX)

Biofrontera logo

Biofrontera (BFRI)

Palisade Bio logo

Palisade Bio (PALI)

BioCardia logo

BioCardia (BCDA)

DWTX Latest News

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report third quarter 2024 financial results on Thursday, November 7, 2024 before the open of the financial markets. Management will also host a webcast and conference call on November 7, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.

What type of business is Dogwood Therapeutics?

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

What sector is Dogwood Therapeutics in?

Dogwood Therapeutics is in the Healthcare sector

What industry is Dogwood Therapeutics in?

Dogwood Therapeutics is in the Biotechnology industry

What country is Dogwood Therapeutics from?

Dogwood Therapeutics is headquartered in United States

What is Dogwood Therapeutics website?

https://www.dwtx.com

Is Dogwood Therapeutics in the S&P 500?

No, Dogwood Therapeutics is not included in the S&P 500 index

Is Dogwood Therapeutics in the NASDAQ 100?

No, Dogwood Therapeutics is not included in the NASDAQ 100 index

Is Dogwood Therapeutics in the Dow Jones?

No, Dogwood Therapeutics is not included in the Dow Jones index

When was Dogwood Therapeutics the previous earnings report?

No data

When does Dogwood Therapeutics earnings report?

Next earnings report date is not announced yet